Prostate Cancer With Comorbidities Increases Venous Thromboembolism
Increased VTE risk among older patients, those with metastases, and those who underwent surgery.
(HealthDay News) -- For men with prostate cancer (PCa), the rate of venous thromboembolism (VTE) is increased with high comorbidity, according to a study published online in Cancer.
Anne G. Ording, Ph.D., from the Aarhus University Hospital in Denmark, and colleagues calculated VTE rate ratios in a nationwide, registry-based cohort study of 44,035 Danish patients diagnosed with PCa from 1995 to 2011 and 213,810 men from the general population, matched for age, calendar time, and comorbidities. The authors examined whether comorbidity interacts with PCa to increase the VTE rate.
The researchers found that during 5 years of follow-up, 849 men from the PCa cohort and 2,360 from the general population had VTE, with a risk of VTE of 2.2 and 1.3%, respectively. Among PCa patients with high comorbidity levels, the 1-year VTE standardized rate was 15 per 1,000 person-years; an interaction between PCa and comorbidity accounted for 29% of that rate. Older patients, those with metastases, those with high Gleason scores, those in the D'Amico high-risk group, and those who underwent surgery had increased VTE risk.
"PCa interacted clinically with high comorbidity levels and increased the VTE rate," the authors write. "Because of the large population burden of PCa, a small reduction in the VTE risk associated with comorbidity may have a positive impact on the prognosis of patients with PCa."
The study was partially funded by the Novo Nordisk Foundation.